(5S)-5-[(1S)-1-(N-t-butoxycarbonylamino)-2-cyclohexylethyl]dihydrofuran-2(3H)-one | 112227-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: (5S)-5-[(1S)-1-(N-t-butoxycarbonylamino)-2-cyclohexylethyl]dihydrofuran-2(3H)-one
• 英文别名: (5S)-5-[(1S)-1-(t-butoxycarbonyl)amino-2-cyclohexylethyl]dihydrofuran-2(3H)-one；(5S,1'S)-5-(1'-((1,1-dimethylethoxy-carbonyl)amino)-2'-cyclohexylethyl)-4,5-dihydrofuran-2-(3H)-one；(5S,1-S)-5-(1-((1,1-dimethylethoxycarbonyl)amino)-2-cyclohexylethyl)-4,5-dihydrofuran2-(3H)-one；(5S,1'S)-5-[1-(1,1-dimethylethoxycarbonylamino)-2-cyclohexylethyl]-dihydrofuran-2(3H)-one；4S,5S-6-Cyclohexyl-5-(t-butyloxycarbonylamino)-gamma-hexanolactone；5(S)-[1(S)-(Boc-amino)-2-cyclohexylethyl]-dihydrofuran-2-(3H)-one；tert-butyl N-[(1S)-2-cyclohexyl-1-[(2S)-5-oxooxolan-2-yl]ethyl]carbamate
• CAS: 112227-09-5
• 化学式: C₁₇H₂₉NO₄
• 分子量: 311.422
• InChiKey: UXCILZJYSIVHNB-KBPBESRZSA-N

物化性质

• 沸点：
  470.9±18.0 °C(predicted)
• 密度：
  1.076±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5S)-5-[(1S)-1-(N-t-butoxycarbonylamino)-2-cyclohexylethyl]dihydrofuran-2(3H)-one 在 正丁基锂 、 sodium chloride 、 ammonium chloride 、 二异丙胺 、 柠檬酸 作用下， 以 四氢呋喃 、 正己烷 、 丙酮 为溶剂， 以86%的产率得到(3S,5S)-5-[(1S)-1-(t-Butoxycarbonyl)amino-2-cyclohexylethyl]-3-(1-hydroxy-1-methylethyl)dihydrofuran-2(3H)-one
  参考文献：
  名称：

  Peptides having renin inhibitory activity, their preparation and use

  摘要：

  化合物的化学式（I）：##STR1## [其中：R.sup.1是具有5个或6个环原子的杂环基团，或--NR.sup.7 R.sup.8，其中R.sup.7是烷基，R.sup.8是可选择取代的苯基，可选择取代的苯基烷基或环烷基；R.sup.2是可选择取代的苯基或萘基；R.sup.3是噻唑基；R.sup.4是环己基或异丙基；R.sup.5是烷基；R.sup.6是烷基]及其盐具有抑制肾素和因此降压活性，并且对于诊断和治疗由肾素-血管紧张素系统失调引起的高血压具有价值。它们可以通过将适当的氨基酸或其衍生物反应在一起制备。

  公开号：

  US05378689A1
• 作为产物：
  描述：

  2-甲基-2-丙基[(2S)-1-环己基-3-氧代-2-丙基]氨基甲酸酯 在 Pd-BaSO₄ 钾硼氢 、 3 A molecular sieve 、 氢气 、 溶剂黄146 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 为溶剂， -78.0 ℃ 、405.3 kPa 条件下， 反应 6.0h， 生成 (5S)-5-[(1S)-1-(N-t-butoxycarbonylamino)-2-cyclohexylethyl]dihydrofuran-2(3H)-one
  参考文献：
  名称：

  Nishi, Takahide; Kataoka, Mitsuru; Morisawa, Yasuhiro, Chemistry Letters, 1989, p. 1993 - 1996

  摘要：

  DOI：

文献信息

• 5-amino-4-hydroxyhexanoic acid derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05643878A1

  公开（公告）日：1997-07-01

  Compounds of formula I ##STR1## or their hydroxy-protected derivatives, and compounds of formula I' ##STR2## wherein T is an acyl radical of formula Z ##STR3## wherein R.sup.z is unsubstituted or substituted hydrocarbyl wherein at least one carbon atom has been replaced by a hetero atom with the proviso that a hetero atom is not bonded directly to the carbonyl to which the radical R.sup.z is bonded, alkyl having two or more carbon atoms, lower alkenyl, lower alkynyl, aryl or unsubstituted or substituted amino, and wherein the radicals R.sub.1, B.sub.1, R.sub.2, R.sub.3, A.sub.1, A.sub.2 and NR.sub.4 R.sub.5 are as defined in the description, and precursors thereof, are described. The compounds have pharmaceutical activity, for example in the treatment of retroviral diseases, such as AIDS.

  公式I的化合物##STR1##或其羟基保护衍生物，以及公式I'的化合物##STR2##，其中T是公式Z的酰基自由基##STR3##，其中R.sup.z是不取代或取代的碳氢化合物，至少有一个碳原子被杂原子替换，但需满足杂原子不直接与R.sup.z连接的酰基相连，烷基含有两个或更多碳原子，低级烯基，低级炔基，芳基或不取代或取代的氨基，且其中R.sub.1、B.sub.1、R.sub.2、R.sub.3、A.sub.1、A.sub.2和NR.sub.4 R.sub.5如描述中定义，以及它们的先驱物，都有药物活性，例如在治疗反转录病毒疾病，如艾滋病。
• HIV protease inhibitors useful for the treatment of aids
  申请人：MERCK & CO. INC.

  公开号：EP0534511A1

  公开（公告）日：1993-03-31

  Compounds of the form,         A-G-J    wherein A is an amine protecting group or urethane, G a dipeptide isostere and J a small terminal group are described. They are distinguished by tetrahydrofuryl or tetrahydropyranyl substituents, and the like. These compounds are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

  形式为A-G-J的化合物被描述，其中A是胺保护基或脲醚，G是二肽同分异构体，J是小的末端基团。它们以四氢呋喃基或四氢吡喃基取代等方式进行区分。这些化合物在抑制HIV蛋白酶、预防或治疗HIV感染以及治疗艾滋病方面具有用途，无论是作为化合物、药学上可接受的盐、药用组合成分，还是与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。
• Antiviral ethers of aspartate protease substrate isosteres
  申请人：Ciba-Geigy Corporation

  公开号：US05663200A1

  公开（公告）日：1997-09-02

  Antiretroviral compounds (which are effective, for example, against HIV) of the formula I ##STR1## in which R.sub.1 is an acyl radical lower-alkoxyl-lower-alkanoyl whose lower alkoxy radical is unsubstituted or is substituted by halogen, phenyl, lower alkoxy or a heterocyclic radical selected from piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolidinyl, thiazolyl, indolyl or 4H-1-benzopyranyl which is unsubstituted or substituted by oxo, hydroxyl, amine, lower alkyl, lower-alkoxycarbonyl and/or phenyl-lower-alkoxycarbonyl; lower alkanoyl which is unsubstituted or is substituted by one of the said unsubstituted or substituted heterocyclic radicals; arylcarbonyl or heterocyclylcarbonyl which are substituted by heterocyclyl or heterocyclyl-lower-alkyl; phenyl-lower-alkanoyl which is substituted by hydroxyl and lower alkyl; or arylsulfonyl; or the residue of an amino acid which is defined in accordance with the description (and which may be acylated on the amino nitrogen by one of the abovementioned acyl radicals); R.sub.2 and R.sub.3 are in each case cyclohexyl, cyclohexenyl, phenyl, naphthyl or tetrahydronaphthyl which are unsubstituted or substituted by lower alkyl, phenyl, cyanophenyl, phenyl-lower-alkyl, halogen, halo-lower-alkyl, cyano, hydroxyl, lower alkoxy, phenyl-lower-alkoxyl, pyridyl-lower-alkoxy, lower-alkoxy-lower-alkoxy, lower-alkoxycarbonyl-lower-alkoxy, carboxyl-lower-alkoxy, hydroxyl-lower-alkoxy, carbamoyl-lower-alkoxy, cyano-lower-alkoxy, and phenyl-lower-alkanesulfonyl which is unsubstituted or substituted by halogen; R.sub.4 is lower alkyl, cyclohexyl or phenyl; and R.sub.5 is lower alkyl; and n is 1 or 2, or salts thereof, are novel.

  抗逆转录病毒化合物（例如对抗HIV有效）的化学式为I ##STR1## 其中R.sub.1是酰基基团的低烷氧基-低烷酰基，其低烷氧基团未取代或被卤素、苯基、低烷氧基或从哌啶基、吡咯啉基、四氢吡喃基、四氢呋喃基、噻唑啉基、噻唑基、吲哚基或4H-1-苯并吡喃基中选择的杂环基团取代；未取代或被上述未取代或取代的杂环基团之一取代的低烷酰基；被杂环基或杂环基-低烷基取代的芳基酰基或杂环基酰基；被羟基和低烷基取代的苯基-低烷酰基；或芳基磺酰基；或根据描述定义的氨基酸残基（可能在氨基氮上由上述酰基基团之一酰化）；R.sub.2和R.sub.3分别为环己基、环己烯基、苯基、萘基或四氢萘基，未取代或被低烷基、苯基、氰苯基、苯基-低烷基、卤素、卤代低烷基、氰基、羟基、低烷氧基、苯基-低烷氧基、吡啶基-低烷氧基、低烷氧基-低烷氧基、低烷氧基羰基-低烷氧基、羧基-低烷氧基、羟基-低烷氧基、氨基甲酰基-低烷氧基、氰基-低烷氧基和未取代或被卤素取代的苯基-低烷烷基磺酰基取代；R.sub.4为低烷基、环己基或苯基；R.sub.5为低烷基；n为1或2，或其盐，均为新颖的。
• Renin-inhibitory oligopeptides, their preparation and use
  申请人：Sankyo Company, Limited

  公开号：US05364844A1

  公开（公告）日：1994-11-15

  Compounds of formula (I): ##STR1## A is a carbon-carbon bond or C.sub.1 -C.sub.3 alkylene; B is imino group or C.sub.1 -C.sub.2 alkylene; R.sup.1 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, heterocyclic or optionally substituted amino; R.sup.2 is optionally substituted phenyl or optionally substituted naphthyl; R.sup.3 is thiazolyl, isoxazolyl or imidazolyl; R.sup.4 is isopropyl or cyclohexyl; R.sup.5 and R.sup.6 are C.sub.1 -C.sub.4 alkyl, or, together with the carbon atom to which they are attached, C.sub.3 -C.sub.7 cycloalkyl; R.sup.7 is hydrogen, optionally substituted C.sub.1 -C.sub.6 alkyl group; and R.sup.8 is hydrogen or C.sub.1 -C.sub.4 alkyl. These compounds have renin-inhibitory and, hence, hypotensive activities. The invention also provides a method for the treatment or prophylaxis of hypertension induced by failures in the renin-angiotensin system.

  式(I)的化合物: A是碳-碳键或C.sub.1 -C.sub.3烷基; B是亚胺基或C.sub.1 -C.sub.2烷基; R.sup.1是C.sub.1 -C.sub.4烷基，C.sub.1 -C.sub.4烷氧基，杂环或可选择取代的氨基; R.sup.2是可选择取代的苯基或可选择取代的萘基; R.sup.3是噻唑基，异噁唑基或咪唑基; R.sup.4是异丙基或环己基; R.sup.5和R.sup.6是C.sub.1 -C.sub.4烷基，或者与其连接的碳原子一起是C.sub.3 -C.sub.7环烷基; R.sup.7是氢，可选择取代的C.sub.1 -C.sub.6烷基; R.sup.8是氢或C.sub.1 -C.sub.4烷基。这些化合物具有抑制肾素的作用，因此具有降压活性。本发明还提供了一种治疗或预防由于肾素-血管紧张素系统功能障碍引起的高血压的方法。
• HIV protease inhibitors having polyether substituents
  申请人：MERCK & CO. INC.

  公开号：EP0487270A2

  公开（公告）日：1992-05-27

  Polyether derivatives of the form,         A-G-B-B-J    wherein G is a dipeptide isostere substituted with a polyether, B an amino acid or analog thereof, and J a small terminal group are described. These compounds are useful in the inhibition of DIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

  描述了形式为A-G-B-B-J的聚醚衍生物，其中G是用聚醚取代的二肽同分异构体，B是氨基酸或其类似物，J是一个小的末端基团。这些化合物在抑制DIV蛋白酶、预防或治疗HIV感染以及治疗艾滋病方面具有用途，无论是作为化合物、药学上可接受的盐、药物组成成分，还是与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。